Transient elevation of the tumor markers CA 15-3 and CASA as markers of interstitial lung disease rather than underlying malignancy in dermatomyositis sine myositis

被引:13
作者
Wong, RCW [1 ]
Brown, S
Clarke, BE
Klingberg, S
Zimmerman, PV
机构
[1] Princess Alexandra Hosp, Queensland Hlth Pathol Serv, Div Immunol, Woolloongabba, Qld 4102, Australia
[2] Royal Brisbane Hosp, Queensland Hlth Pathol Serv, Div Chem Pathol, Brisbane, Qld 4029, Australia
[3] Prince Charles Hosp, Queensland Hlth Pathol Serv, Dept Thorac Med, Brisbane, Qld 4032, Australia
[4] Prince Charles Hosp, Queensland Hlth Pathol Serv, Div Anat Pathol, Brisbane, Qld 4032, Australia
关键词
CA; 15-3; dermatomyositis sine myositis; diffuse alveolar damage; interstitial lung disease; MUC1;
D O I
10.1097/00124743-200208000-00005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A 37-year-old woman with severe interstitial lung disease associated with dermatomyositis sine myositis is reported. A thoracoscopic lung biopsy revealed organizing diffuse alveolar damage. Significantly elevated serum levels of the tumor markers CA 15-3 and CASA (cancer-associated serum antigen) were detected, but no evidence of an underlying malignancy (including breast and ovarian) was found on serial clinical and radiologic examinations. These levels gradually normalized as the interstitial lung disease responded to a combination of cyclophosphamide and corticosteroids. The use of the CA 15-3 and CASA assays to measure serum levels of the highly glycosylated, high-molecular-weight mucin MUC1 in interstitial lung disease has not been previously described. Clinicians should therefore be aware that elevation of these tumor markers may reflect the presence of interstitial lung disease rather than an underlying malignancy in patients with dermatomyositis, especially if the levels normalize after successful treatment of the lung disease.
引用
收藏
页码:204 / 207
页数:4
相关论文
共 16 条
  • [1] Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis
    Bandoh, S
    Fujita, J
    Ohtsuki, Y
    Ueda, Y
    Hojo, S
    Tokuda, M
    Dobashi, H
    Kurata, N
    Yoshinouchi, T
    Kohno, N
    Takahara, J
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2000, 59 (04) : 257 - 262
  • [2] DEVINE PL, 1993, CANCER, V72, P2007, DOI 10.1002/1097-0142(19930915)72:6<2007::AID-CNCR2820720636>3.0.CO
  • [3] 2-U
  • [4] AMYOPATHIC DERMATOMYOSITIS (DERMATOMYOSITIS SINE MYOSITIS) - PRESENTATION OF 6 NEW CASES AND REVIEW OF THE LITERATURE
    EUWER, RL
    SONTHEIMER, RD
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1991, 24 (06) : 959 - 966
  • [5] DERMATOMYOSITIS WITHOUT CREATINE-KINASE ELEVATION - A POOR PROGNOSTIC SIGN
    FUDMAN, EJ
    SCHNITZER, TJ
    [J]. AMERICAN JOURNAL OF MEDICINE, 1986, 80 (02) : 329 - 332
  • [6] Interstitial lung disease in polymyositis and dermatomyositis
    Hirakata, M
    Nagai, S
    [J]. CURRENT OPINION IN RHEUMATOLOGY, 2000, 12 (06) : 501 - 508
  • [7] KL-6 - A SERUM MARKER FOR INTERSTITIAL PNEUMONIA
    KOBAYASHI, J
    KITAMURA, S
    [J]. CHEST, 1995, 108 (02) : 311 - 315
  • [8] NEW SERUM INDICATOR OF INTERSTITIAL PNEUMONITIS ACTIVITY - SIALYLATED CARBOHYDRATE ANTIGEN KL-6
    KOHNO, N
    KYOIZUMI, S
    AWAYA, Y
    FUKUHARA, H
    YAMAKIDO, M
    AKIYAMA, M
    [J]. CHEST, 1989, 96 (01) : 68 - 73
  • [9] Serum KL-6 in adult patients with polymyositis and dermatomyositis
    Kubo, M
    Ihn, H
    Yamane, K
    Kikuchi, K
    Yazawa, N
    Soma, Y
    Tamaki, K
    [J]. RHEUMATOLOGY, 2000, 39 (06) : 632 - 636
  • [10] Cyclosporine treatment for polymyositis/dermatomyositis: Is it possible to rescue the deteriorating cases with interstitial pneumonitis?
    Maeda, K
    Kimura, R
    Komuta, K
    Igarashi, T
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 1997, 26 (01) : 24 - 29